Ron Philip is president and CEO of Orbital Therapeutics, and a member of the board of directors of City Therapeutics. With more than 30 years of experience across biopharma companies and management consulting, Mr. Philip is a proven leader with extensive experience in building companies, leading organizational growth and guiding teams through the development of novel therapies.

Prior to joining Orbital, Mr. Philip served as the CEO of Spark Therapeutics, where he led the company through the commercial launch of the first approved gene therapy for a genetic disease, LUXTURNA® (voretigene neparvovec-rzyl). He led Spark’s transition and growth from founder-led to a fully integrated standalone business as part of the Roche Group. Mr. Philip also pivoted Spark’s platform to target larger disease areas, acquired technologies and therapeutic assets through business development efforts, and oversaw the initiation and build of a state-of-the-art 600,000 sq. ft. Gene Therapy Innovation Center that will open in 2026. He served as chief operating officer and chief commercial officer in prior roles at Spark.

Before joining Spark, Mr. Philip spent a decade at Pfizer and Wyeth, where he held several senior leadership roles, including regional president for Africa/Middle East, head of global business unit strategy, head of business development search and evaluation, and commercial development lead within Pfizer’s innovative products business. Earlier, he worked at Deloitte Consulting in the strategy and operations practice and at Merck & Co. in the company’s manufacturing and marketing divisions.

Mr. Philip currently serves as a board member at the Academy of Natural Sciences of Drexel University in Philadelphia, at the Chamber of Commerce for Greater Philadelphia, at Life Sciences Pennsylvania and was previously an active board member of Cure Duchenne. He is a graduate of Drexel University.